O.MartucciA.CesareoM.NucciC
DiMarchi, who was a vice president at Eli Lilly and involved in GLP-1 research there, until he left the company in 2003, is that many diseases may share the same root causes, even though we label them and treat them as distinct: This is an endocrine disease, this is a cardiovascular disease, this is a brain disease. This root-cause theory suggests that a wide range of conditions can be treatable with one drug class, sometimes through pathways in the brain and the immune system
The inactive form is considered a precursor as it gets converted into an active peptide GLP-1 (7-37) by cleaving a single arginine residue (Fig
OSR / NBMI by Boyd Haley Boyd Haley developed a compound over 20 years ago which may be superior to all other chelators, including DMSA, DMPS, ALA, or EDTA
Thats why how you store creatine matters more than just checking the date on the label
27 reported that the supplementation of leonurine to the culture medium during early embryo development reduced intracellular ROS levels and increased GSH levels in blastomeres
